New and current preventive treatment options in actinic keratosis
- PMID: 28805940
- DOI: 10.1111/jdv.14375
New and current preventive treatment options in actinic keratosis
Abstract
Actinic keratosis (AK) is a characteristic skin lesion on skin areas of subjects with mainly phototype I and phototype II, or with specific genetic factors and who are exposed to prolonged ultraviolet radiation. AK may be considered a precursor of in situ squamous cell carcinoma (SCC), a type of non-melanoma skin cancer (NMSC). However, it is still not possible to predict which AK lesions will develop into SCC. Early treatment of AK is therefore recommended. Despite the increasing number of patients with AK developing into SCC, to date, there is still no clear suggestion of therapeutic strategy for AK. Current treatment consists of a multitude of topical lesion-directed or field-directed therapies or a combination of both. Recently, orally administered nicotinamide has shown to significantly reduce rates of new NMSC and AK in high-risk patients. This study aims to provide an update on the most relevant information about AK and to provide an insight into current and new treatment options.
© 2017 European Academy of Dermatology and Venereology.
Similar articles
-
Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.Cutis. 2011 Apr;87(4):201-7. Cutis. 2011. PMID: 21644496 Review.
-
[The real face of actinic keratosis: field of cancerisation and squamous cell carcinoma].Eur J Dermatol. 2012 Dec;22 Suppl 1:5-9. doi: 10.1684/ejd.2012.1872. Eur J Dermatol. 2012. PMID: 23269757 Review. French.
-
What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents.Cutis. 2012 May;89(5):241-50. Cutis. 2012. PMID: 22768439 Review.
-
Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.G Ital Dermatol Venereol. 2013 Dec;148(6):693-8. G Ital Dermatol Venereol. 2013. PMID: 24442053
-
Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression.J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1138-1146. doi: 10.1111/jdv.14703. Epub 2018 Jan 12. J Eur Acad Dermatol Venereol. 2018. PMID: 29150868 Free PMC article.
Cited by
-
Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.Ther Clin Risk Manag. 2018 Oct 4;14:1879-1885. doi: 10.2147/TCRM.S145779. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30323610 Free PMC article. Review.
-
Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.PLoS One. 2020 May 15;15(5):e0232146. doi: 10.1371/journal.pone.0232146. eCollection 2020. PLoS One. 2020. PMID: 32413042 Free PMC article.
-
Chemical Peels in Skin Cancer: A Review.J Clin Aesthet Dermatol. 2020 Feb;13(2):53-57. Epub 2020 Feb 1. J Clin Aesthet Dermatol. 2020. PMID: 32308785 Free PMC article. Review.
-
Topical GZ21T Inhibits the Growth of Actinic Keratoses in a UVB-Induced Model of Skin Carcinogenesis.JID Innov. 2023 May 6;3(4):100206. doi: 10.1016/j.xjidi.2023.100206. eCollection 2023 Jul. JID Innov. 2023. PMID: 37533581 Free PMC article.
-
How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results.J Clin Med. 2021 Oct 15;10(20):4736. doi: 10.3390/jcm10204736. J Clin Med. 2021. PMID: 34682859 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials